William Daniel Chapman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
William Daniel Chapman has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
A. I. Ford
Oklahoma State University-Center for Health Sciences
1 shared publicationAllison Lapins
1 shared publicationAndrew Creed
1 shared publication- Anya Mazur-Mosiewicz
Oklahoma State University Center for Health Sciences, Department of Behavioral Sciences, 1111 West 17th Street, Tulsa, OK 74107, United States
1 shared publication Bryce Casteigne
1 shared publicationDennis Bourdette
Department of Neurology, Oregon Health & Science University, Portland, USA
1 shared publication
Latest Publications
- 31 July 2023
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 23 (9) , 521-529
Polypharmacy in Multiple Sclerosis: Prevalence, Risks, and Mitigation Strategies
Purpose of Review Polypharmacy, the use of ≥ 5 medications, is common in people with multiple sclerosis and is associated with negative outcomes. The use of multiple medications is common for symptom management in people with multiple sclerosis, but risks drug-drug interactions and additive side effects. Multiple sclerosis providers should therefore focus on the appropriateness and risks versus benefits of pharmacotherapy in each patient. This review describes the prevalence and risks associated with polypharmacy in people with multiple sclerosis and offers strategies to identify and mitigate inappropriate polypharmacy. Recent Findings Research in people with multiple sclerosis has identified risk factors and negative outcomes associated with polypharmacy. Medication class-specific investigations highlight their contribution to potentially inappropriate polypharmacy in people with multiple sclerosis. Summary People with multiple sclerosis are at risk for inappropriate polypharmacy. Multiple sclerosis providers should review medications and consider their appropriateness and potential for deprescribing within the context of each patient.
- 31 July 2023
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 23 (9) , 521-529
Polypharmacy in Multiple Sclerosis: Prevalence, Risks, and Mitigation Strategies
Purpose of Review Polypharmacy, the use of ≥ 5 medications, is common in people with multiple sclerosis and is associated with negative outcomes. The use of multiple medications is common for symptom management in people with multiple sclerosis, but risks drug-drug interactions and additive side effects. Multiple sclerosis providers should therefore focus on the appropriateness and risks versus benefits of pharmacotherapy in each patient. This review describes the prevalence and risks associated with polypharmacy in people with multiple sclerosis and offers strategies to identify and mitigate inappropriate polypharmacy. Recent Findings Research in people with multiple sclerosis has identified risk factors and negative outcomes associated with polypharmacy. Medication class-specific investigations highlight their contribution to potentially inappropriate polypharmacy in people with multiple sclerosis. Summary People with multiple sclerosis are at risk for inappropriate polypharmacy. Multiple sclerosis providers should review medications and consider their appropriateness and potential for deprescribing within the context of each patient.
- Open Access
- 1 December 2021
- Published by Elsevier in Biomarkers in Neuropsychiatry
- Vol. 5
Diagnostic biomarkers in Alzheimer’s disease
- 1 December 2021
- Published by Elsevier in Biomarkers in Neuropsychiatry
- Vol. 5
Open AccessDiagnostic biomarkers in Alzheimer’s disease
- 9 October 2018
- Published by American Psychological Association (APA) in Journal of Pediatric Neuropsychology
- Vol. 4 (3-4) , 113-126
Why children fail the Test of Memory Malingering: Review of false positive performance in pediatric studies.
The Test of Memory Malingering (TOMM) is a commonly utilized performance validity test currently recommended for pediatric use with children as young as 5 years of age. Yet, a small sample of children struggles to pass the TOMM due to true cognitive difficulties. The systematic search and review identified the reported cases of false positive and overall failing TOMM performance in children. The goal of this project was to increase the understanding of the cognitive constructs and minimum cognitive abilities necessary for children to pass the TOMM. The secondary goal was to use the existing data to suggest clinical guidelines related to use of the TOMM with children.
- 9 October 2018
- Published by American Psychological Association (APA) in Journal of Pediatric Neuropsychology
- Vol. 4 (3-4) , 113-126
Why children fail the Test of Memory Malingering: Review of false positive performance in pediatric studies.
The Test of Memory Malingering (TOMM) is a commonly utilized performance validity test currently recommended for pediatric use with children as young as 5 years of age. Yet, a small sample of children struggles to pass the TOMM due to true cognitive difficulties. The systematic search and review identified the reported cases of false positive and overall failing TOMM performance in children. The goal of this project was to increase the understanding of the cognitive constructs and minimum cognitive abilities necessary for children to pass the TOMM. The secondary goal was to use the existing data to suggest clinical guidelines related to use of the TOMM with children.